• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Sedatives for patients receiving general anesthesia questioned

, 26 August 2020/in E-News /by 3wmedia

Although sedatives are often administered before surgery, a randomized trial finds that among patients undergoing elective surgery under general anesthesia, receiving the sedative lorazepam before surgery, compared with placebo or no premedication, did not improve the self-reported patient experience the day after surgery, but was associated with longer time till removal off a breathing tube (extubation) and a lower rate of early cognitive recovery.
Patients scheduled for surgery may experience considerable stress and anxiety. Benzodiazepine (a class of sedatives) premedication is frequently used to reduce anxiety but also causes amnesia, drowsiness, and cognitive impairment. Treating anxiety is not necessarily associated with a better perioperative (before and after surgery) experience for the patient. More needs to be known about the efficacy of preoperative anxiety treatment to better counsel patients to make informed decisions, according to background information in the article.
Axel Maurice-Szamburski, M.D., of the H

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:37Sedatives for patients receiving general anesthesia questioned

Selenide protects heart muscle in the wake of cardiac arrest

, 26 August 2020/in E-News /by 3wmedia

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center.

Mark Roth, Ph.D., and colleagues in the Fred Hutch Basic Sciences Division have published their findings.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:45Selenide protects heart muscle in the wake of cardiac arrest

High-pressure oxygen can effectively treat fibromyalgia

, 26 August 2020/in E-News /by 3wmedia

Fibromyalgia is almost impossible to diagnose. The chronic pain syndrome strikes an estimated 1 in 70 Americans, most of them women. The disorder is often triggered by head trauma, a neurological infection, or severe emotional stress, and is characterized by symptoms such as musculoskeletal pain, fatigue, memory loss and mood swings. Fibromyalgia is often mistaken for other culprits and most patients suffer months, even years, of unrelenting pain before being properly diagnosed. And once diagnosed, patients enjoy little respite because few therapies have been found to be effective in assuaging its symptoms.

A new study by Tel Aviv University researchers may turn the tide. The research found that women with fibromyalgia were able to drastically reduce, or even eliminate, their use of pain medication following hyperbaric oxygen treatment. The study was led by the late Prof. Eshel Ben-Jacob of TAU’s School of Physics and Astronomy and Rice University’s Center for Theoretical Biological Physics, Dr. Shai Efrati of TAU’s Sagol School of Neuroscience and Assaf Harofeh Medical Center, and Prof. Dan Buskila from Soroka Medical Center, and was conducted by a team of scientists from TAU, Rice University, Assaf Harofeh Medical Center, Ben-Gurion University, and Tel Aviv Sourasky Medical Center.

The TAU researchers believe they have also identified the primary factor causing fibromyalgia: the disruption of the brain mechanism for processing pain. ‘As a physician, the most important finding for me is that 70 percent of the patients could recover from their fibromyalgia symptoms,’ said Dr. Efrati. ‘The most exciting finding for the world of research, however, is that we were able to map the malfunctioning brain regions responsible for the syndrome.’

Hyperbaric oxygen chambers expose patients to pure oxygen at higher-than-atmospheric pressures and are commonly used to treat patients with embolisms, burns, carbon monoxide poisoning, and decompression sickness.

The clinical trial, which exposed participants to two months of hyberbaric oxygen therapy, found significant changes in the brain activity and symptoms of 70 percent of participants. The trial involved 60 women who had been diagnosed with fibromyalgia at least two years earlier. Half of the 48 patients who completed the therapy received 40 hyperbaric oxygen treatments

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:25High-pressure oxygen can effectively treat fibromyalgia

Proton therapy has fewer side effects in oesophageal cancer patients

, 26 August 2020/in E-News /by 3wmedia

New research by scientists at the University of Maryland School of Medicine has found that oesophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.

Working with colleagues at the Mayo Clinic in Rochester, Minnesota and the MD Anderson Cancer Center in Dallas, Texas, Michael Chuong, MD, an assistant professor of radiation oncology at the school, compared two kinds of X-ray radiation with proton therapy, an innovative, precise approach that targets tumours while minimizing harm to surrounding tissues.

The researchers looked at nearly 600 patients and found that proton therapy resulted in a significantly lower number of side effects, including nausea, blood abnormalities and loss of appetite.

‘This evidence underscores the precision of proton therapy, and how it can really make a difference in cancer patients’ lives,’ said Dr. Chuong.

Patients with oesophageal cancer can suffer a range of side effects, including nausea, fatigue, lack of appetite, blood abnormalities and lung and heart problems. Proton therapy did not make a difference in all of these side effects, but had significant effects on several.

The results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC). The centre will provide one of the newest and highly precise forms of radiation therapy available, pencil beam scanning (PBS), which targets tumours while significantly decreasing radiation doses to healthy tissue. This technique can precisely direct radiation to the most difficult-to-reach tumours. EurekAlert

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:32Proton therapy has fewer side effects in oesophageal cancer patients

Clinicians ap Watson to accelerate DNA analysis

, 26 August 2020/in E-News /by 3wmedia

IBM Watson Health has announced that it is collaborating with more than a dozen leading cancer institutes to accelerate the ability of clinicians to identify and personalize treatment options for their patients. The institutes will apply Watson’s advanced cognitive capabilities to reduce from weeks to minutes the ability to translate DNA insights, understand a person

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:40Clinicians ap Watson to accelerate DNA analysis

Imaging technique could make brain tumour removal safer

, 26 August 2020/in E-News /by 3wmedia

A major challenge in surgically removing tumours, particularly in the brain, is to cut out as much cancer as possible while leaving healthy tissue alone.
Currently available imaging tools to aid doctors during brain surgery, such as MRI, are time-consuming, expensive and do not provide continuous guidance.
Researchers have developed a way of using a different imaging technology, called optical coherence tomography, to help surgeons quickly and safely distinguish healthy from cancerous tissue.

Brain surgery is famously difficult for good reason: When removing a tumour, for example, neurosurgeons walk a tightrope as they try to take out as much of the cancer as possible while keeping crucial brain tissue intact

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:27Imaging technique could make brain tumour removal safer

High-Tech prostate scan may boost prostate cancer detection

, 26 August 2020/in E-News /by 3wmedia

An innovative fusion of MRI and ultrasound might be a better way to detect and assess prostate cancer, while helping men avoid unnecessary biopsies, researchers say.
The technology blends real-time imaging from both MRI and ultrasound devices, allowing doctors to more accurately direct the biopsy needle that draws cell samples from suspected tumours.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:35High-Tech prostate scan may boost prostate cancer detection

Use of pocket-sized ultrasound device reduces need for further testing in clinical settings

, 26 August 2020/in E-News /by 3wmedia

Results from a study presented at The International Liver Congress 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.

The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.

PUDs offer a comparable performance to standard ultrasonography, however the accuracy of a physical examination is often poor meaning that further tests are required. This study assessed whether adding the use of PUD to physical examination could lead to a reduction in the rate of additional tests.

Of the 1,962 patients included in the study:

726 (37%) were inpatients, 510 (26%) were hepatology outpatients and 726 (37%) were recruited from GPs
Gallstones (37%), ascites – excessive accumulation of fluid in the abdominal cavity (17%), pleural effusion (13%), urinary stones (13%) and urinary retention (12%) accounted for more than 90% of the clinical questions, confirmed by PUD in 66% of cases
The overall frequency of further tests needed after PUD was 37%
The rate of agreement between findings of the PUD and additional tests was 89%
This study found that after basic training, the use of a PUD offers a simple and effective way to improve the accuracy of diagnosis and reduce the number of tests a patient needs. EurekAlert

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:42Use of pocket-sized ultrasound device reduces need for further testing in clinical settings

Hybrid cochlear implants for common form of hearing loss may benefit millions

, 26 August 2020/in E-News /by 3wmedia

People with a common form of hearing loss not helped by hearing aids achieved significant and sometimes profound improvements in their hearing and understanding of speech with hybrid cochlear implant devices, according to a new multicenter study led by specialists at NYU Langone Medical Center.

In the study researchers at 10 medical centres and private clinics in the United States implanted hybrid cochlear implants into one ear of 50 men and women. All study volunteers had badly damaged high-frequency, inner-ear hair cells, which prevented them from understanding speech, especially in the presence of background noise. All still had sufficient low-frequency hearing, which allowed them to tell apart some sounds and forestalled any use of a regular cochlear implant.

A year after receiving the device, 45 study participants showed overall improvement in their hearing and speech recognition, and no one

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:22Hybrid cochlear implants for common form of hearing loss may benefit millions

Withholding angiotensin receptor blockers after surgery increases risk of postoperative death

, 26 August 2020/in E-News /by 3wmedia

Withholding angiotensin receptor blockers (ARBs) for longer than two days after surgery is associated with a significantly increased risk of postoperative death, according to a study of more than 30,000 patients in the VA health care system by researchers at UC San Francisco and the San Francisco VA Medical Center (SFVAMC).

ARBs are prescribed for high blood pressure, heart disease and kidney disease, explained lead author Susan M. Lee, MD, an SFVAMC anesthesiologist and UCSF clinical instructor.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:39:222020-08-26 14:39:30Withholding angiotensin receptor blockers after surgery increases risk of postoperative death
Page 137 of 229«‹135136137138139›»

Latest issue of International Hospital

April 2024

19 May 2025

Medical milestone: World’s first human bladder transplant successfully performed

16 May 2025

Mindray launches premium ultrasound system to enhance diagnostic capabilities

15 May 2025

World’s first personalised CRISPR therapy treats child with rare metabolic disorder

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription